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Background: The Forkhead box M1 (FOXM1) is an oncogenic transcription factor and plays a significant role in cell
EMT, proliferation, metastasis in a multitude of human solid tumors including colorectal cancer (CRC). However, the
underlying molecular mechanisms by which FoxM1 contributes to epithelial-to-mesenchymal (EMT) and metastasis
have not been fully elucidated in CRC.
Methods: In our study, we investigated FOXM1 protein expression in 87 CRC tissue specimens, invasive lymph
nodes and adjacent paired normal colorectal tissues by immunohistochemical analysis. Then we transfected FOXM1
specific shRNA into SW620 cells to examine effect of FOXM1 on proliferation, colony formation, migration and
invasion in vitro. Western blotting and real-time PCR were used to detect the protein and mRNA expression of
FOXM1 and EMT-related markers.
Results: FOXM1 was overexpressed in CRC tissues, invasive lymph nodes and CRC cell lines. FoxM1 overexpression
was significantly associated with lymph node metastasis (P < 0.001), and tumor recurrence (P < 0.001). Moreover,
downregulation of FOXM1 in SW620 cells by shRNA approach inhibited cell growth, clonogenicity, migration and
invasion in vitro. In addition, decreased FOXM1 expression in SW620 cells reversed the acquisition of EMT phenotype
by up-regulating E-cadherin, as well as reduction Vimentin and Snail expressions at protein and mRNA levels.
Conclusions: FOXM1 may regulate CRC cells metastasis through EMT program and FOXM1 may be a potential target
for treatment of CRC.
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Colorectal cancer (CRC) is the third most common can-
cer and the third leading cause of cancer death in men
and women in the United States. Although early detec-
tion tests and treatments have been improved in clinical
practice, including modified surgical techniques and
neoadjuvant chemotherapy combined with radiation
therapy in CRC patients, the 5-year survival rate is de-
creasing to 12.5% in the advanced CRC patients who* Correspondence: professorzxg@hotmail.com
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unless otherwise stated.have metastasis of distant organs [1-3]. Therefore, there
is an urgent need to identify novel prognostic hallmarks
and to improve on current understanding of the molecu-
lar mechanisms of advanced CRC.
The transcription factor Forkhead box M1 (FOXM1)
is an oncogenic transcription factor belongs to the FOX
protein super family that shares an evolutionarily con-
served winged helix DNA-blinding domain [4,5]. Large-
scale gene expression analysis by means of microarrays
have demonstrated that FoxM1 is one of the most com-
mon overexpressed genes in a multitude of human solid
tumors [6], including hepatocellular carcinomas [7], pan-
creatic cancer [8], breast cancer [9], ovarian cancer [10],
colorectal cancer [11] and lung cancer [12], suggestinghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Many studies have reported that FOXM1 is known as a
key regulator of the cell cycle by regulating the transi-
tion from G1 to S and G2 to M phase and mitosis
[13,14], playing a positive effect on cell proliferation.
Futhermore, enhanced expression of FoxM1 is associ-
ated with advanced stage, lymph node matastasis and
acts as an independent prognostic factor in non-small
cell lung cancer (NSCLC) [15]. Beyond that cell prolifer-
ation, FOXM1 also plays important roles in tumor
angiogenesis, EMT, invasion, and metastasis [9,16-20].
The actual occurrence of EMT serves as a dominant role
in invasion and metastasis of colon cancer [21], which is
regulated by a various signal pathways, such as FOXM1-
PLAUR [22], FOXM1-caveolin-1 signaling pathway [23].
Emerging evidences suggest that enhanced FoxM1 levels
lead to the acquisition of EMT phenotype, which con-
tributes to tumor cell aggressiveness along with a series
of molecule changes of epithelial or mesenchymal
markers [24]. On the contrary, for example, downex-
pression of FOXM1 in RNAi-mediated gastric cancer
cells reversed the EMT phenotype and upregulated the
expression of epithelial markers E-cadherin, as well as
downregulated the expression of mesenchymal markers
ZEB1, ZEB2 and Vimentin [25]. However, the precise
function and internal mechanisms of FOXM1 in colo-
rectal cancer cells EMT and metastasis remain still
indistinct.
In our present study, we detected the expression of
FOXM1 in colorectal tumor tissue specimens by immuno-
histochemical staining from 87 CRC patients and investi-
gated the relationships among mediated gene knockdown
of FOXM1 on SW620 cells and EMT, proliferation, migra-
tion and invasion in vitro. Our results show that the
downregulation of FoxM1 inhibits the cell migration, in-
vasion, and proliferation of SW620 cells and reverses the
EMT phenotype by up-regulating epithelial cell markers
E-cadherin, as well as down-regulating the expression of
the mesenchymal cell markers Vimentin and Snail at pro-
tein and mRNA levels. The results provide supportive evi-
dence that FOXM1 may be an effective therapeutic target
in CRC.
Materials and methods
Human colorectal cancer tissues and colon cancer cell lines
Human colorectal cancer tissues were obtained from 87
patients at the Department of General Surgery, the First
Affiliated Hospital of Soochow University from 2008-
2013. Each tumor tissue and adjacent normal colon
tissue (at least 2cm distance from the tumor site) were
collected from the same patient with a clear histological
diagnosis of CRC who had received no any therapy be-
fore sample collection. The researches were supported
by the Independent Ethics Committee (IEC) of the FirstAffiliated Hospital of Soochow University and all pa-
tients were provided written informed consent. Human
colon cancer cell lines HCT116, SW620, SW480, LOVO
and DLD-1 were purchased from the Chinese Academy
of Sciences (Shanghai, China). All five cell lines were
maintained in DMED supplemented with 10% fetal bo-
vine serum (Sijiqing Biological Engineering Materials
Co., Hangzhou, China) and cultured at 37°C in a hu-
midified atmosphere containing 5% CO2.
Immunohistochemistry (IHC)
The protein of FOXM1 of 87 human colorectal cancer
tissue samples and adjacent normal colorectal tissues
was detected through immunohistochemical staining
(IHC). IHC was performed using the streptavidin-
peroxidase coujugate method. Surgical specimens were
fixed in 10% formalin and embedded in paraffin. Briefly,
the paraffin-embedded tissues were serially cut into 4μm
sections, dewaxed, and rehydrated. Sections of paraffin-
embedded tissues were then blocked with peroxide in
methanol, and nonspecific immunoglobulin binding was
blocked by incubation with 10% normal goat serum for
15min. After rinsing with PBS, the sections were incu-
bated at room temperature for 1h with Foxm1 poly-
clonal rabbit-anti-human antibody (Abcam, UK) at
1:200 dilution. After a PBS rinse, slides were then incu-
bated for 25min at room temperature with biotinylated
goat-anti-rabbit immunoglobulin (1:1000, Zhongshan
Biotechnology, China) followed by incubation with
peroxidase-conjugated streptavidin for 20min. Finally, the
slides were stained with fresh 0.05% 3, 3′-diaminobenzi-
dine (DAB), counterstained with hematoxylin, dehydrated,
cleared in xylene, and fixed. Histological assessment was
performed as described previously [26]. Immunostaining
was independently examined by two clinical pathologists
who were blinded of the patient outcome. Five high-power
fields (400 ×magnification) were randomly counted for
each section. The brown staining on the cytoplasm was
read as positive reactivity for FOXM1. The presence of
brown colored granules on the cytoplasm was taken as a
positive signal, and was divided by color intensity into not
colored, light yellow, brown, tan and is recorded as 0, 1,
2, 3, respectively. We also chose five high-power fields
from each slice and scored them. Positive cell rate of <
25% was a score of 1, positive cell rate of 25 ~ 50% was
a score of 2, positive cell rate of 51 ~ 75% was a score
of 3, positive cell rate of >75% was a score of 4. The
scores for FOXM1 positivity and staining intensity were
multiplied to obtain a final score, which determines
FOXM1 expression as (− = 0; + =1-4; ++ = 5–8; +++ =
9–12). In our current study, we classified all of the
samples into the high expression group (++ or +++)
and the low expression group (− or +) according to the
protein expression.
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cell line SW620
Human FOXM1 shRNA (5′-GGACCACUUUCCCUA
CUUU-3′) and control-shRNA (5′-GGACCUGUAUGC
GUACAUU-3′) were synthesized by GenePharma (shanghai,
china). SW620 cells were transfected with shFOXM1 or
control-shRNA using Lipofectamine 2000 (Invitrogen,
Life Technologies), according to the manufacturer’s
instructions.
Quantitative real-time reverse transcription PCR (QRT-PCR)
The mRNA expression of FOXM1, E-cadherin, Vimentin
and Snail in SW620 cells after FOXM1-shRNA transfec-
tion were quantified by real-time RT-PCR. Total RNA
was extracted from cells and tumor tissues using TRIzol
Reagent (Invitrogen, Life Technologies) and cDNA was
synthesized from 2μg of RNA using the First Strand
cDNA Synthesis Kit (Fermentas) according to the manu-
facturer’s instructions. QRT-PCR was carried out using
Power SYBR® Green PCR Master Mix (ABI, USA) on the
7500 real time PCR system (ABI, life technology). The
β-actin was used as a loading control for each specific
gene. Each experiment was performed three times and
each sample was tested in triplicate. The sequences for











AGTCAGTCAG-3′. The PCR conditions consisted of
5min at 95°C 1cycle, 30sec at 95°C, 30sec at 55°C,
30sec at 72°C and 7min at 72°C 40cycles. The 2-ΔΔCT
method was applied to analyze the relative changes in
gene expression [27].
Protein extraction and western blot analysis
Whole protein extracts from SW620 at 72h following
shRNA transfection or untransfection were lysed in ice-
cold RIPA lysis buffer (Beyotime Inc., NanTong, China)
according to manufacturer’s protocol. From each sample
preparation 50μg of whole protein was separated by
SDS-PAGE and then transferred to PVDF membranes
(Millipore, USA). Standard Western blotting was per-
formed using a polyclonal rabbit antibody against human
FoxM1 (1:1000, Abcam, UK), mouse anti-human E-
cadherin (1:1000, Abcam, UK), rabbit anti-human Vimentin
(1:1000, Abcam, UK), rabbit anti-human Snail (1:500,
Abcam, UK) and rabbit anti-β-actin (1:1000., Beyotime,china). The signals from the primary antibody was
amplified by HRP conjugated anti-mouse IgG or anti-
rabbit IgG (1:1000; Beyotime, china) and detected with
Enhanced Chemiluminescence Plus kit (Beyotime,
China).MTT assays of cell viability
Briefly, 24hours after transfection, SW620 cells of three
groups were digested, re-suspended and seeded at a
density of 4 × 103 cells/well in 96-well culture plates,
After 24h,48h and 72h of incubation in complete
medium, cells were added 20μl MTT solution (5mg/ml)
at 37°C for 4hours. Then supernatants were removed
and formazan crystals were dissolved in 150μl DMSO.
After gentle shaking for 10 minutes, the absorbance (A)
at 490nm was measured by using a microplate reader.
Each sample was four replicate wells and the experiment
was repeated three times.Clonogenic assays
Clonogenic assay was conducted to examine the effect
of FoxM1-shRNA on cell growth in SW620 cells, as de-
scribed previously [9]. 4 × 105 SW620 cells were plated
in a 6-well plate. After 24h of transfection, the cells were
trypsinized, and 1,000 single viable cells were plated in
three 6-well plates. The cells were then incubated for
14days at 37°C in the condition of 5% CO2/5% O2/90%
N2. Colonies were stained with 0.1% crystal violet,
washed with water, and counted ten random fields
manually. The colonies containing at least 100 cells were
scored. The surviving fraction in FoxM1-shRNA trans-
fected SW620 cells was normalized to untreated control
cells with respect to clonogenic efficiency.Wound healing assay
Wound healing assay was adopted to test the migration
ability of colon cancer cells. In our study, SW620 cells
were digested after transfection by specific shRNA and
control shRNA to human Foxm1 for 24h in 6-well
plates, 2 × 105 cells were plated in 24-well plates, when
cell confluence reached approximately 100%, the old
medium was removed and the monolayer was wounded
by scratching with a 10-μl sterile pipette tip lengthwise
along the chamber, then cells were washed three times
with PBS and cultured with serum-free medium at 37°C.
Images of cells migrating into the wound were photo-
graphed at 0h, 24h, 48h and 72h using an inverted
microscope. Wound width (μm) was measured using
OpenLab software. Wound healing rate = (0h scratch
width - 24h/48h or 72h scratch width)/0h scratch
width × 100%. The experiments were repeated three
times.
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The migratory and invasive activity of the FoxM1 or
control shRNA-transfected SW620 cells was tested using
the Transwell chambers equipped with a pore size of
8μm (Corning, USA) according to the manufacturer’s
recommendations. After 24h of transfection, 2 × 104
SW620 cells per well were resuspended in serum-free
DMEM medium and seeded into the Transwell inserts
either uncoated (for migration assay) or coated (for inva-
sion assay) with growth factor-reduced Matrigel (BD
Biosciences, Bedford, MA), whereas the lower chambers
were filled with 500μl DMEM with 10% FBS. After 24h
incubation at 37°C, the cells on the upper side of the in-
sert filter were completely removed by wiping with a
cotton swab, and the cells that had invaded were fixed in
methanol and stained with 0.1% crystal violet. The cells
were counted manually under an inverted microscope
on five random fields (scale bar =200μm). Each experi-
ment was repeated in triplicate.
Statistical analysis
Data are expressed as the means ± standard deviation
(SD). Significant differences between the groups were
determined using the student’s t-test and Chi-square
test. A value of P < 0.05 was considered to indicate a sta-
tistically significant difference. All statistical analyses
were performed with SPSS17.0 software (SPSS Inc,
Chicago, IL, USA).
Results
FoxM1 is over-expressed in human colorectal cancer
patients
To investigate whether FoxM1 is highly expressed in
CRC tissues, we first detected the expression of FoxM1Figure 1 FoxM1 is highly expressed in human CRC patients. (A-D): Foxm1
nodes from immunohistochemical staining. The protein expression of FOXM1
respectively. Scale bar = 100μm. (E): QRT-PCR analyses of colon cancer tissues
Foxm1 mRNA expression levels were significantly higher in colon cancer tissuprotein in the 87 primary colorectal tumors and paired
adjacent normal colorectal tissue specimens as well as
invasive lymph nodes using immunohistochemical stain-
ing. Our immunostaining results showed a FoxM1-
positive staining in the nucleus and/or cytoplasm of
colorectal tumor cells and invasive lymph nodes,
whereas there was negative or weakly positive staining of
FoxM1 in the paired adjacent normal colorectal tissues
(Figure 1A-D). To further confirm the expression of
FoxM1 in colon cancer, we detected the expression of
FoxM1 in fresh colon cancer tissues, metastatic lymph
nodes and adjacent normal tissues from four same pa-
tients. Real-time PCR was subjected to examine the
mRNA levels. Consistent with the level of FoxM1 pro-
tein expression determined using immunostaining ana-
lyses, primary colorectal tumors and metastatic lymph
nodes had significantly higher levels of FoxM1 mRNA
expression than did surrounding normal colorectal tissue
from 4 patients by QRT-PCR analysis, the difference be-
tween them was statistically significant (Figure 1E p < 0.01).
These results indicated that FoxM1 is commonly over-
expressed in human colorectal tumors, particularly in
metastatic lymph nodes.
Relationship between Foxm1 expression and
clinicopathologic parameters in CRC patients
To further assess the clinical relevance of FoxM1 over-
expression in CRC patients, we then analyzed the rela-
tionship between the level of FoxM1 expression levels
and clinicopathologic parameters in 87 CRC patients
using immunohistochemical staining. As shown in
Table 1, we observed that high expression of Foxm1 was
significantly correlated with regional lymph nodes metasta-
sis (χ2 = 9.184, p = 0.002) and tumor recurrence (χ2 = 8.025,protein expression in CRC cells, normal colon cells and invasive lymph
was negative (A), mild positive (B), positive (C), strong positive (D),
, invasive lymph nodes and adjacent normal tissues from 4 CRC patients.
es and invasive lymph nodes than paired adjacent normal colon tissues.
Table 1 Relationship between FoxM1 expression from IHC and clinicopathological factors of 87 CRC patients
Clinic parameters Total FoxM1 expression χ2 P value
None or low High
Age(years) T=87 N=35(40.2%) N=52(59.8%)
<65 33(37.9%) 15(45.5%) 18(54.5%) 0.604 0.437
>=65 54(62.1%) 20(37.0%) 34(63.0%)
Gender
Male 42(48.3%) 19(45.2%) 23(54.8%) 0.847 0.357
Female 45(51.7%) 16(35.6%) 29(64.4%)
Tumor size
<5cm 56(64.4%) 20(35.7%) 36(64.3%) 1.333 0.248
>=5cm 31(35.6%) 15(48.4%) 16(51.6%)
Tumor location
Right colon 33(37.9%) 11(33.3%) 22(66.7%) 1.052 0.305
Left colon and rectum 54(62.1%) 24(44.4%) 30(55.6%)
TNM Stage
Stage I/II 42(48.3%) 19(45.2%) 23(54.8%) 0.847 0.357
Stage III/IV 45(51.7%) 16(35.6%) 29(64.4%)
Histological differentiation
Well 28(32.2%) 12(42.9%) 16(57.1%) 1.873 0.392
Moderate 46(52.9%) 20(43.5%) 26(56.5%)
Poor 13(14.9%) 3(23.1%) 10(76.9%)
Lymph node metastasis
Yes 47(54.0%) 12(25.5%) 35(74.5%) 9.184 0.002***
No 40(56.0%) 23(57.5%) 17(42.5%)
Tumor recurrence
Yes 53(60.9%) 15(28.3%) 38(71.7%) 8.025 0.005***
No 34(39.1%) 20(58.8%) 14(41.2%)
***P < 0.001.
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ciated with other clinicopathologic features, such as age,
gender, tumor size, tumor location, TNM stages and histo-
logical differentiation (all p > 0.05).
FoxM1 is up-regulated in CRC cell lines and associated
directly with migration ability of colorectal cancer cells
To evaluate the baseline expression levels of FoxM1 in a
series of human colorectal cancer cell lines, including
HCT116, LOVO, DLD-1, SW480, SW620, we detected
the mRNA and protein expression of FoxM1 by real-
time PCR and Western Blot analyses, respectively. Our
studies evidenced that SW620 cells showed the highest
expression of FoxM1, especially in relation to the
SW480 cell line (Figure 2A&B). To further test whether
the expression levels of FoxM1 were related to migration
ability of CRC cells, we measured the effects of FoxM1
expression levels on cancer cell migration by transwell
systems between SW480 and SW620 cells; we found thatthe numbers of migratory SW620 cells were more dra-
matically higher than those of SW480 cells (Figure 2C,
P < 0.001).Deletion of FoxM1 gene down-regulated the mRNA and
protein levels of FoxM1 expression in SW620 cells
In order to explore the effect the shRNA silencing
FoxM1 expression in SW620 cells, SW620 cells were
transfected with the FoxM1 shRNA (shFoxM1) and
control-shRNA; after 72h, the total protein and RNA of all
transfected and untransfected cells were extracted and an-
alyzed by Western blots and real-time PCR. As shown in
Figure 3A-C, FoxM1 expression was distinctly decreased
at mRNA and protein levels in transfected cells with
FoxM1 shRNA compared with control-shRNA transfected
cells and untreated cells. The results showed that the spe-
cific shRNA to FoxM1 effectively suppressed the expres-
sion of FoxM1 in SW620 cells.
Figure 2 Expression of FoxM1 in CRC cell lines. (A): Western blot analysis of FOXM1 protein expression in CRC cancer cell lines (Upper). The ratio
between the grey levels of FOXM1 and β-actin of the each CRC cell lines through Western blotting (Lower). (B): Real-time PCR analysis of FOXM1
mRNA expression in HCT116, LOVO, DLD-1, SW480, SW620 cells. (C): the migration ability of SW480 and SW620 colon cancer cells. The data showed
that SW620 cells presented higher levels of migration ability than SW480 cells. The experiments were repeated three times.
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and clonogenicity in SW620 cells
In order to determine the effect of FoxM1 on the pro-
liferation of SW620 cells in vitro, the proliferation
curves were detected by MTT assays at 24h, 48h, 72h
after 24h of transfection. We found that SW620 cells
which down-regulated the FoxM1 expression experi-
enced a significant inhibition of cell viability compared
with control-shRNA and untreated cells respectively
(Figure 4A, both P < 0.01).
To further examine whether the knockdown of FoxM1
gene reduces the clonogenic formation of SW620 cells,
after 24h of tranfection, 2 × 103/well of SW620 cells
were plated in 6-well plates and cultured 14days to ob-
serve the numbers of colony formation. The results
showed that the numbers of colonies in FoxM1-
depleted SW620 cells displayed an apparent reduction
compared with control-shRNA and untreated cells re-
spectively (Figure 4B, p < 0.05).
Knockdown of FoxM1 expression by shRNA induced a
cellular morphologic change and EMT-related mRNA and
protein expressions in SW620 cells
As illustrated in Figure 5A, SW620 cancer cells have a typ-
ical mesenchymal morphology characterized by elongated,spindle-shaped phenotype. To examine whether down-
regulation of FoxM1 expression could change cell
morphology, we transfected FoxM1 shRNA (shFOXM1)
and control shRNA into SW620 cells; after 72hours of
transfection, we found that in the monolayer culture
system, SW620 cellular morphology changed from an
elongated, spindle-shaped, mesenchymal phenotype to
a more rounded, epithelial-like phenotype after knock-
down of FoxM1 expression and observation under the
microscopy. The results indicated that knockdown of
FoxM1 expression altered mesenchymal morphology of
SW620 cells and reversed the typical epithelial-to-
mesenchymal transition.
To further understand the internal molecular mechan-
ism of mesenchymal-to-epithelial transition when FoxM1
was down-expressed, we investigated the EMT-related
protein expression levels in transfected and untransected
SW620 cells by western blotting (Figure 5B). The knock-
down of FoxM1 gene by shRNA led to markedly reduce
the mesenchymal marker Vimentin and Snail protein ex-
pression, whereas significantly increased the protein level
of E-cadherin, which is a typical epithelial marker. Con-
sistent with the real-time PCR analysis (Figure 5C-E), the
down-regulation of FoxM1 expression significantly en-
hanced E-cadherin expression and attenuated Vimentin
Figure 3 Deletion of FoxM1 gene down-regulated the expression of
FoxM1 in SW620 cells by shRNA. Western blotting (A-B) and qRT-PCR
analyses (C) showed that the level of FoxM1 expression was
remarkably decreased in stably FoxM1-depleted SW620 cells at
the mRNA and protein levels, respectively. β-actin as a loading
control. Each experiment was repeated three times.
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cells compared with those of control cells at the mRNA
levels. The results demonstrated that FoxM1 played an
important role in epithelial-to-mesenchymal transition
regulation in CRC.
Effect of altered FoxM1 expression on SW620 colon
cancer cells migration and invasion in vitro
Previous studies had suggested that down-expression of
FoxM1 promoted E-cadherin expression and suppressed
Vimentin and Snail expression, which were pronoun-
cedly associated with EMT regulation. To determine
whether attenuated FoxM1 expression reversed theEMT process and further inhibited the migration and in-
vasion in the colorectal cancer cells, we first explored
the role of FoxM1 in CRC cell migration via the wound
healing assay. The FoxM1-decreasing SW620 cells
showed comparatively slower migration towards the
wound space; however, control shRNA cells and un-
treated cells migrated aggressively and nearly closed the
wound at 72h after transfection (Figure 6A-B, ** p < 0.01).
Similar results arosed in the transwell migration system
(Figure 6C-left, D-upper, *** P < 0.001).
Consistent with the impact of altered FOXM1 expres-
sion on the invasion of SW620 cancer cells in vitro,
transwell invasion assay revealed that FoxM1 shRNA-
transfected cells showed a low level of penetration
through the Matrigel-coated membrane compared with
the control cells (Figure 6C-right, D-lower, *** P < 0.001).
All these results clearly show that FoxM1 participates in
EMT process and promotes the migration and matasta-
sis in colorectal cancer cells.
Discussion
FOXM1 is commonly regarded as an oncogenic tran-
scription factor and abnormal expression and activation
of FOXM1 is associated with the proliferation and me-
tastasis of human colon cancer cells, as an independent
poor prognostic factor and conversely correlated with
poor OS and MFS in CRC patients [11,17,28]. In the
present study, FOXM1 protein expression was examined
using immunohistochemisty analysis in CRC patients
and we detected that FOXM1 was highly expressed in
most human primary CRC tissues, particularly in in-
vaded lymph nodes, whereas lowly expressed in adjacent
normal colon tissues. Meanwhile, the strong relation-
ships among FOXM1 expression and clinicopathology
features had been investigated in CRC patients by IHC,
our results indicated that FOXM1 overexpression was
significantly associated with regional lymph nodes metas-
tasis and tumor recurrence, suggesting important roles of
FOXM1 in human colorectal cancer tumorigenesis and
distant metastasis. The results show that FOXM1 has the
potential to be a novel therapeutic target in CRC.
A mounting body of evidence notes that FOXM1 is a
critical regulator of both the G1/S and G2/M transitions
through the cell cycle progression, which is required for
proliferative expansion during tumor progression [5].
Knockdown of FoxM1 inhibits expression of JNK1 and
cyclinA2, which are involved in G1-S progression and in
accumulation of cells in G2/M [29]. Previous research
had revealed the role of FOXM1 in cell growth; in-
creased expression of Foxm1 in Rosa26-Foxm1b trans-
genic mice directly regulated the cell-cycle progression
of colon tumor cells by promoting S-phase progression
and entry into mitosis [30]. Consistently, our current
studies suggested that inhibition of FOXM1 expression
Figure 4 Effect of FoxM1 on the proliferation and clonogencity of SW620 cells. (A): Down-regulation of FoxM1 expression inhibited the proliferation
of SW620 cells compared with the Untreated cells and control-shRNA transfected cells by MTT assay. Figures are curves of SW620 cell growth after
transfection for 24, 48 and 72h by MTT assays. (B): Down-regulation of FoxM1 expression reduced the numbers of colonies significantly in SW620 cell
line. Cell colonies were stained with 0.1% crystal violet and the colonies containing above 100 cells were counted manually. All data are presented as
the means ± SD of three independent experiments.
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proliferation and colony forming capability compared
with that control-shRNA SW620 cells. Besides the cell
proliferation capability of FOXM1, aberrant regulation
of FOXM1 is a leading factor of malignancy tumor me-
tastasis [10]. In our five CRC cell lines, HCT116,
SW620, SW480, LOVO, DLD-1, western blot and qRT-
PCR analyses showed that FOXM1 expression levels
were significantly increased, especially in SW620 cells.
Meanwhile, we found that SW620 cells exhibited the
much higher metastatic ability, revealing that FOXM1
overexpression may promote the tumor metastasis.
As shown in our wound healing assays and transwell mi-
gration/invasion systems, down-expression of FOXM1
remarkly inhibited the wound healing, migration and inva-
sion of FOXM1-depleted SW620 cells. All our in vitro
assays suggest a pivotal role for the FOXM1 in the metas-
tasis progression of colorectal cancer and FOXM1 silen-
cing could efficiently control the CRC cells metastasis.
Metastasis of tumor is a multistep and complex process
including local invasion, intravasation, survival in circula-
tion, extravasation, micrometastasis formation and meta-
static colonization [31]. For tumor cells metastatic
programs, the expression of FOXM1 may regulate a series
of interrelated events including the expession of caveolin-
1 [23], VEGF [17,18], MPP-2 and MPP-9 [19], which are
important to epithelial–mesenchymal transition (EMT),
angiogenesis and metastasts. Importantly, a mountingbody of work suggests that EMT, by which epithelial cells
acquire mesenchymal characteristics leading to increased
migratory and invasive potential of the cancer cells, has a
critical role in metastasis [32,33]. Recently, numerous ob-
servations support the idea that the occurrence of EMT is
closely associated with FOXM1 signaling activation. EMT
has been reported as a pivotal program in several human
solid cancers, including CRC [34], gastric cancer [25] and
breast cancer [16], which is considered as the first step of
tumor invasion and metastasis. Recent research shows
that FOXM1c overexpression upregulates uPAR expres-
sion in pancreatic cancer cells and promotes EMT. Con-
trariwise, inhibition of FOXM1c expression suppressed
uPAR expression by siRNA; furthermore, FOXM1c silen-
cing expression could be targeted to reverse the acquiring
of EMT phenotype in L3.7 cells [35]. Our present findings
are consistent with these previous results. we transfected
specific shRNA to FOXM1 into SW620 cells, which have
a typical mesenchymal phenotype and high expression of
FOXM1. We found that this transfection greatly inhibited
FOXM1 mRNA and protein expression. Additionally, the
SW620 cells reversed the acquisition of the EMT pheno-
type, changing from an elongated, spindle-shaped, mesen-
chymal phenotype to a more rounded, epithelial-like
phenotype. As shown in recent studies, targeting FoxM1
signaling by novel small interference RNA silencing tech-
nique or miR-200 family members would be useful for re-
versing the EMT phenotype, which would likely result in
Figure 5 FoxM1-depleted SW620 cells underwent morphological change and effect of FoxM1 on the reversal of EMT in SW620 cells. (A): SW620
cells were transfected with shFOXM1 or control shRNA and incubated for 72hours. Photomicrographs suggested SW620 cells suffered morphologic
changes of mesenchymal-to-epithelial transition after knockdown of FOXM1 expression. Scale bar = 50μm. (B): Expression of EMT markers was
determined by western blots, β-actin as a loading control. (C-E): Total RNA was extracted from transfected and untransfected SW620 cells by
shFOXM1 or control shRNA and subjected to real-time PCR for E-cadherin, Vimentin, and Snail relative mRNA expression. The data were calculated with
the 2-△△CT Method.
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cells [24]. Interestingly, knockdown expression of FOXM1
down-regulated mesenchymal cell markers Vimentin and
Snail and up-regulated the epithelial cell marker E-
cadherin, which acted as key regulators in the process of
epithelial-to-mesenchymal transition (EMT). Emerging
evidences suggest that many EMT-inducing transcriptionfactors such as Snail and ZEB1 have been found to be as-
sociated with expression of FOXM1 [15,24,36], which
leads to tumor aggressiveness and metastasis. E-cadherin
is a typical epithelial marker and loss of E-cadherin is a
significant hallmark of EMT and can be mediated by the
repressor binding directly to E-box motifs within the
proximal E-cadherin promoter, such as snail [37,38].
Figure 6 Effect of altered FOXM1 expression on colorectal cancer cell migration and invasion in vitro. (A): Wound healing assays were carried out
at 24h after transfection in 24-well plates, when cell confluence rate reached above 90% and a linear wound across the monolayer was done. The
wound gap was photographed every 24h, the gap width was measured (μm) using Open Lab software. (B): the wound rate was calculated and
displayed graphically as described in the Materials and Methods. (C-D): SW620 cells of three groups were digested and resuspended in serum-free
culture medium and allowed to migrate toward the lower chamber with coated or uncoated matrigel for 24h. Invading cells were stained with 0.1%
crystal violet and counted manually. C-Left: transwell migration assay, Right: transwell invasion assay. (D): The number of invading SW620 cells by cell
migration (upper) and invasion (lower) assay was counted manually. Each experiment was repeated thrice independently. Scale bar = 200μm
in those figures.
Yang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:40 Page 10 of 12Snail is one of zinc-finger transcription factors that
have been known as an essential player in the aggressive
phenotype of EMT [39,40]. Increasing evidence suggests
that Snail acts as a critical role during embryonic devel-
opment and is essential for the formation of the fibro-
blasts during inflammation [41-43]. Moreover, Snail is
highly expressed in CRC, especially in lymph node me-
tastasis of CRC [44]. Consistent with our studies,FOXM1 has an intimate relationship with the expression
of Snail in CRC cells. Recent studies demonstrated that
ectopic FOXM1 activation increased Snail activity through
AKT signaling in hepatocellular carcinoma cells isolated
from FoxM1b Tg;Arf−/− mice. Increased FoxM1b levels
induce EMT by activating AKT and subsequently increas-
ing GSK-3β, which enhanced Snail expression [45]. In
addition, new researches have verified that Foxm1 directly
Yang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:40 Page 11 of 12bound to and increased activity of Snail1 promoter,
namely Snail1 is a direct downstream transcriptional tar-
get of Foxm1 in the radiation-induced pulmonary fibrosis
and lung adenocarcinoma progression [43,46]. Taken to-
gether, our current study strongly suggests that FOXM1
signaling has important roles in CRC cells proliferation
and aggressiveness; thus, it is indicated that an intervening
strategy targeting FOXM1 signaling in colon cancer may
be of clinical value.
Conclusions
In summary, our studies have demonstrated that overex-
pression of FOXM1 is associated with distant lymph me-
tastasis and tumor recurrence, and knockdown of
FOXM1 by shRNA inhibited cell proliferation, migration
and invasion of human colon cancer cells. In addition,
we determined that downexpression of FOXM1 reversed
the acquisition of EMT phenotype and upregulated the
expression of E-cadherin, while decreasing Snail and
Vimentin expression. Based on these studies, we con-
clude that FOXM1 may serve as a promising therapeutic
target of CRC.
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